Although, in our series, none of the six SNUC showed SMARCB1 loss, we could confirm low survival rates in patients with SMARCB1-deficient carcinomas, suggesting that, regardless of the histological features observed in PDSNCs, this marker identifies a specific biological entity with a potential impact for prognosis and targeted therapeutic options [36]. This evidence concerns the gene SMARCB1 and carcinoma.